Background and aims-Administration of omeprazole to healthy volunteers was recently reported to increase proximal duodenal mucosal bicarbonate secretion. As human oesophagus also secretes bicarbonate, the hypothesis was tested that omeprazole may stimulate oesophageal bicarbonate secretion and thus contribute to the therapeutic efficacy of the drug in gastro-oesophageal reflux disease. Subjects and methods-In nine healthy volunteers, oesophageal "steady state" perfusion of a 10 cm open segment of distal oesophagus was performed twice in random order. The volunteers were pretreated with either 60 mg/day omeprazole for three days and 80 mg intravenous omeprazole before perfusion or 600 mg/day ranitidine for three days and 50 mg/h intravenously during the perfusion. Saliva and samples of aspirate from the perfused oesophagus and stomach were collected and bicarbonate concentrations were measured. Results-The median rates (95% confidence intervals) of intrinsic oesophageal bicarbonate secretion, corrected for contaminating salivary and gastric bicarbonate, were 89 (33-150) and 121 pmol/h/10 cm (p>0.5) in omeprazole and ranitidine treated subjects respectively. Salivary and gastric bicarbonate contaminating the oesophagus accounted for 14% and 3%, respectively, of total oesophageal bicarbonate output. Conclusions-Bicarbonate secretory capacity of the human oesophagus is less than previously assumed, and the clinical relevance of intrinsic oesophageal bicarbonate for mucosal defence may be overestimated. As omeprazole and ranitidine did not affect bicarbonate secretion differently there was no evidence that omeprazole acts on bicarbonate secretory celis in the oesophageal mucosa. (Gut 1997; 40: 582-586) 
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Bicarbonate secretion by the human oesophagus -supposed to originate in submucosal glands -has recently been implicated as a protective mechanism against damage from refluxed gastric acid.' 2 However, reported secretory rates varied from 156 to 489 ,umol/ h/10 cm, which clouds the interpretation that intrinsic oesophageal bicarbonate secretion is important for clearance of refluxed gastric acid compared with the salivary component of acid neutralisation. The findings of an incremental increase in oesophageal pH with repeat swallows3 ' and stimulation of salivary bicarbonate secretion by oesophageal acidification, suggesting the existence of an oesophagosalivary reflex,2 5 have previously established the importance of salivary bicarbonate. On the other hand, in vitro experiments suggest that intrinsic oesophageal bicarbonate secretion rates of about 160 ,umol/h are capable of neutralising 1 ml of acid with a pH >2 0,1 which seems representative of the residual volume present within the oesophageal lumen after an episode of reflux and bolus clearance by peristalsis.3 ' The proton pump inhibitor omeprazole has recently been shown to enhance duodenal mucosal bicarbonate secretion in healthy volunteers independent of its gastric acid inhibitory effect.6 This increase in duodenal neutralising capacity is likely to add to the well documented superiority of omeprazole in duodenal ulcer healing over histamine H2 receptor antagonists. In the treatment of gastro-oesophageal reflux disease omeprazole is again superior to histamine H2 receptor antagonists.7 8 It remains to be established whether omeprazole has a stimulatory effect of its own on oesophageal bicarbonate secretion, which might contribute to the therapeutic gain. We have, therefore, made an attempt to measure human oesophageal bicarbonate secretion more accurately to allow assessment of the in vivo effect of omeprazole on intrinsic oesophageal bicarbonate secretion in healthy volunteers.
Methods

SUBJECTS
Ten healthy volunteers (six men and four women, median age 26, range years), with no past or current gastrointestinal or other medical diseases, were studied by a protocol approved by the Copenhagen and Frederiksberg ethics committee. Each participant gave written informed consent.
EXPERIMENTAL DESIGN
Nine of the subjects were studied twice after an overnight fast. Before perfusion the subjects were randomly pretreated with either omeprazole (60 mg/day for three days and 80 mg intravenously one hour before perfusion) or ranitidine (600 mg/day for three days and 50 mg/h intravenously during perfusion). Firstly, a double lumen gastric tube (16 French, AN 10 Anderson Samplers Inc, Atlanta, GA, USA) was introduced nasally and placed in the distal antrum. The infusion port was located 8 cm proximal to the aspiration port. Secondly, a similar double lumen tube was introduced orally and placed in the distal oesophagus. The infusion port was located 10 cm orally to the aspiration ports, which were positioned 35 cm from the incisors (Figure) . Experiments were performed with subjects in a semireclined position. The oesophagus was perfused (Ivac 560 Pump, NC Nielsen, Glostrup, Denmark) with isotonic saline (5 ml/min; pH 7 0) using The pH values of the aspirates were immediately measured by a glass electrode attached to a standard pH meter (PHM82, Radiometer, Copenhagen, Denmark), which was calibrated daily by standard buffer solutions at pH 4, 7, and 10.
Concentrations of bicarbonate in 100 [LI aliquots of saliva and aspirates from the oesophagus and the stomach were determined in triplicate (Coming 965 Carbon Dioxide Analyzer, Coming Ltd., Halstead, UK). This method corresponds to the back titration method,9 which has previously been shown to determine oesophageal bicarbonate secretion more accurately than the pH/pCO2 method.2 Before analysis the samples were gassed with CO2 free nitrogen for five minutes to remove dissolved carbon dioxide. The Coming analyser was calibrated daily against 1-0 and 2-5 mM NaHCO3. The between day variability, expressed as coefficient of variation, was 12% (n=20) and 6% (n=20) respectively.
To determine the contamination of the oesophageal test segment with saliva, amylase concentrations were measured in samples of saliva and aspirates from the oesophagus by an enzymatic, colorimetric method using maltoheptaoside (Merck, Darmstadt, Germany) as a substrate.
Activities of [51Cr] and concentrations of phenol red were determined both in oesophageal and gastric aspirates and served as markers for recovery and contamination of the respective test segment. Activities of [5'Cr] were measured by gamma spectrometry. Concentrations of phenol red were measured spectrophotometrically at 560 nm after being made alkaline (pH= 1 1) by a 4+1 dilution with a 0 5 M Na2PO4 solution. VALIDATION 
STUDIES
In vitro bicarbonate studies The accuracy of the Coming 965 carbon dioxide analyser for determination of bicarbonate concentrations was tested by performing 10 measurements on each of 0 5, 1 0, 2-5, 5 0, and 10 0 mM standard bicarbonate solutions. These results were compared with those obtained by using the original back titration method.
In vivo infusion of bicarbonate In three of the subjects additional experiments were performed to determine the accuracy of the perfusion method for measurement of oesophageal bicarbonate secretion. After a 30 minute equilibration period, basal bicarbonate secretion was determined for 30 3  79  46  0  127  21  4  4  25  1  0  88  8  2  5  150  22  12  91  13  351  6  150  164  3  121  23  11  7  122  50  1  129  26  4  8  33  25  3  284  16  4  9  89  6  3  203  89  8 Discussion The results of this study support recent findings suggesting that human oesophagus has the ability to secrete bicarbonate into the lumen.' 2 The origin of bicarbonate has been attributed to submucosal glands present in human oesophagus.12 Rabbit oesophagus, which is devoid of submucosal glands, does not seem to secrete bicarbonate,'3 which emphasises the role of these glands in bicarbonate secretion by the oesophagus. The functional relevance of intrinsic oesophageal bicarbonate secretion and other protective mechanisms, such as salivary bicarbonate and mucous secretion and oesophageal mucous secretion, motor activity, mucosal blood flow, and epithelial cell proliferation and resistance, is to maintain mucosal integrity after exposure to aggressive factors, such as acid and pepsin. "1 The importance of the low rates of oesophageal bicarbonate secretion for neutralisation of gastric acid seems, however, overestimated in the light of the part played by salivary bicarbonate and peristaltic movements. In the present study, the rates of bicarbonate secretion into saliva were about 10-fold higher than the output of intrinsic oesophageal bicarbonate. Similarly, other studies have clearly shown the importance of saliva for acid clearance in the oesophagus3 4 and the capability of oesophageal peristalsis to reduce the bolus from a reflux period to less than 1 ,ul. Nevertheless, the median rates of oesophageal bicarbonate secretion found would still be sufficient to neutralise a volume < 1 ml with a pH >2.5,2 which is consistent with the previously noted non-salivary component of luminal acid clearance.3 4 '5 Furthermore, the oesophagus seems to have additional capacity for luminal acid clearance, as it has been shown that topical acidification stimulates bicarbonate secretion. '6 Isolation of intestinal segments by occluding balloons for prevention of contaminating fluids from adjacent segments provides an attractive model for the in vivo study of ionic transport in the gastrointestinal tract. This approach has proved useful in the human duodenum and jejunum, but the application of two occluding balloons in the oesophagus, by using a commercially available, specially designed tube, '7 was unsuccessful in our hands in preliminary experiments. The subjects had great difficulty in tolerating the pressure from the inflated balloons and a free aspiration flow could not be sustained. ,imol/h/10 cm, respectively, and the same low contamination by salivary and gastric bicarbonate, but these investigators achieved a much lower recovery in the perfused segment than that in the present study.
As reflux of acidic gastric contents to the distal oesophagus may neutralise the small amounts of secreted bicarbonate, suppression of gastric acid secretion is mandatory to obtain valid results of oesophageal bicarbonate secretion. In previous studies on human oesophageal bicarbonate secretion ranitidine was used for acid suppression.' 2 We compared the effect of omeprazole on oesophageal bicarbonate secretion with that of ranitidine, because of recent findings that omeprazole enhances bicarbonate secretion in the duodenum.6 Also the finding that high doses of ranitidine (about 2 g daily) are inferior to omeprazole in reducing the number of reflux episodes, despite equally significant reduction in gastric acid secretion, '8 
